Reference entries for individual research peptides. Each entry documents classification, structural profile, and the areas of preclinical investigation associated with the compound — sourced from published literature summaries, not usage instructions.
Derived from a fragment of human gastric juice protein; widely referenced in gut and soft-tissue repair models.
SPEC. NO. 021A synthetic fragment of thymosin beta-4, studied for its role in actin regulation and wound-healing models.
SPEC. NO. 032A pentapeptide ghrelin-receptor agonist studied for its comparatively selective GH-release profile in animal models.
SPEC. NO. 033A GHRH analog studied for extended half-life relative to native GHRH, often referenced alongside GHRP compounds.
SPEC. NO. 041A GLP-1 receptor agonist studied extensively in metabolic and glucose-regulation literature.
SPEC. NO. 044A GIP-based peptide engineered to activate GLP-1, GIP, and glucagon receptors together.
SPEC. NO. 037A stabilized GHRH(1-44) analog, also studied in clinical literature under an approved indication.
SPEC. NO. 065A naturally occurring copper tripeptide widely studied in wound-healing and skin literature.
SPEC. NO. 072A GHK-Cu, BPC-157, and TB-500 combination formulated for tissue-repair research.
SPEC. NO. 073The GLOW combination plus KPV, studied alongside anti-inflammatory and dermal-research literature.
SPEC. NO. 058A synthetic analog of an endogenous immunomodulatory peptide, studied in the context of anxiolytic research models.
SPEC. NO. 061A mitochondrial-derived peptide studied for proposed roles in metabolic homeostasis and exercise-response research.
Each entry is assigned a reference number the way a lab notebook or certificate of analysis would index a sample — it's an internal indexing convention for this site, not a regulatory or pharmacopeial identifier. Entries are added and revised as the underlying literature develops; check the "last reviewed" date on each page.